Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

ClinicalTrials.gov ID: NCT02373813

Public ClinicalTrials.gov record NCT02373813. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy of etanercept monotherapy compared to methotrexate monotherapy on maintenance of remission in participants with rheumatoid arthritis (RA) who were on etanercept plus methotrexate therapy. This is a multicenter, randomized withdrawal, double-blind controlled study in participants with rheumatoid arthritis on etanercept plus methotrexate therapy who are in very good disease control for 6 months prior to study entry. The study will consist of a 30-day screening period, a 24-week open label run-in period, a 48-week double-blind treatment period and a 30-day safety follow-up period.

Study identification

NCT ID
NCT02373813
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
371 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 19, 2015
Primary completion
Dec 5, 2019
Completion
Dec 5, 2019
Last update posted
Jan 10, 2023

2015 – 2019

United States locations

U.S. sites
74
U.S. states
22
U.S. cities
71
Facility City State ZIP Site status
Research Site Birmingham Alabama 35205
Research Site Birmingham Alabama 35294
Research Site Huntsville Alabama 35801
Research Site Glendale Arizona 85306
Research Site Mesa Arizona 85202
Research Site Phoenix Arizona 85037
Research Site Scottsdale Arizona 85258
Research Site Escondido California 92025
Research Site Fontana California 92335
Research Site Hemet California 92543
Research Site Huntington Beach California 92646
Research Site La Jolla California 92037
Research Site Murrieta California 92563
Research Site Orange California 92868
Research Site Sacramento California 95817
Research Site Santa Maria California 93454-6945
Research Site Torrance California 90502
Research Site Tustin California 92780
Research Site Victorville California 92395
Research Site West Hills California 91307
Research Site Doral Florida 33126
Research Site Fort Lauderdale Florida 33309
Research Site Gainesville Florida 32607
Research Site Miami Florida 33126
Research Site Miami Florida 33144
Research Site Orlando Florida 32806
Research Site Palm Harbor Florida 34684
Research Site Pensacola Florida 32514
Research Site St. Petersburg Florida 33705
Research Site Tampa Florida 33613
Research Site Lawrenceville Georgia 30046
Research Site Boise Idaho 83702
Research Site Meridian Idaho 83642
Research Site Blue Island Illinois 60406
Research Site Skokie Illinois 60076
Research Site Springfield Illinois 62703
Research Site Granger Indiana 46530
Research Site Baton Rouge Louisiana 70809
Research Site New Orleans Louisiana 70121
Research Site Wheaton Maryland 20902
Research Site Ann Arbor Michigan 48109
Research Site Detroit Michigan 48202
Research Site Grand Rapids Michigan 49546
Research Site Kalamazoo Michigan 49008
Research Site Lansing Michigan 48910
Research Site Lansing Michigan 48917
Research Site Springfield Missouri 65807
Research Site St Louis Missouri 63141
Research Site Clifton New Jersey 07012
Research Site Freehold New Jersey 07728
Research Site Newark New Jersey 07103
Research Site Albuquerque New Mexico 87102
Research Site Brooklyn New York 11201
Research Site Great Neck New York 11021
Research Site New York New York 10021
Research Site Charlotte North Carolina 28204
Research Site Greenville North Carolina 27834
Research Site Oklahoma City Oklahoma 73103
Research Site Duncansville Pennsylvania 16635
Research Site Pittsburgh Pennsylvania 15224
Research Site Wynnewood Pennsylvania 19096
Research Site Wyomissing Pennsylvania 19610
Research Site Charleston South Carolina 29406
Research Site Orangeburg South Carolina 29118
Research Site Jackson Tennessee 38305
Research Site Knoxville Tennessee 37909-1900
Research Site Carrollton Texas 75007
Research Site Corpus Christi Texas 78404
Research Site Cypress Texas 77429
Research Site League City Texas 77573
Research Site Plano Texas 75024
Research Site San Antonio Texas 78229
Research Site Webster Texas 77598
Research Site Danville Virginia 24541

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02373813, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 10, 2023 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02373813 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →